HONG KONG, Jan. 26, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been accepted by the Center for Drug Evaluation (CDE)...
Hence then, the article about akeso s gumokimab monoclonal antibody il 17 new drug application for the treatment of moderate to severe psoriasis accepted by nmpa was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA )
Also on site :
- Amazon's ‘Supportive’ Skechers Wedge Sandals Are ‘Great for Traveling’ and Just $31 Before the Big Spring Sale
- Beloved Singer-Songwriter Behind the Defining Rock Anthem of the 2000s Turns 51
- On This Date in 1979, an Iconic '70s Band Released Their Last Top 10 Hit